Robert Bindert Huizinga, EVP of Research at Aurinia Pharmaceuticals Inc. (AUPH), sold 42,500 shares at $19.76 ($885K) on 2021-09-10, disclosed to the SEC on 2021-09-14.
Open-market sale of $885k AUPH by EVP of Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.76 | 5,000 | $99K | 11.2% |
| 2 | $19.76 | 5,000 | $99K | 11.2% |
| 3 | $19.83 | 5,000 | $99K | 11.2% |
| 4 | $19.83 | 5,000 | $99K | 11.2% |
| 5 | $21.75 | 22,500 | $489K | 55.3% |
| Total | $20.83 avg | 42,500 |
| $885K |
| 100% |
| Filing → |
| AUPH | SELL | 2021-09-22 | $1.6M | — | Filing → |
| AUPH | SELL | 2021-09-08 | $92K | — | Filing → |